Department of Thoracic and Cardiovascular Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, China.
Genscript Biotech Corporation, Genscript 860 Centennial Ave, Piscataway, NJ, 08854, USA.
Sci Rep. 2017 Oct 20;7(1):13659. doi: 10.1038/s41598-017-13696-3.
Early and convenient diagnosis is urgently needed for acute Stanford type A aortic dissection (AAAD) patients due to its high mortality within the first 48 hours. Circulating microRNAs (miRNAs) are promising biomarkers of cardiovascular diseases, however, little is known about circulating miRNAs involved in AAAD. Here, the blood serum was sampled from 104 AAAD+ patients and 103 age-matched donors. Initial screening was conducted using the TaqMan Low Density Array followed by RT-qPCR confirmation. According to the two-phase selection and validation process, we found that miR-25, miR-29a and miR-155 were significantly elevated, while miR-26b was markedly decreased in AAAD+ serum samples compared with AAAD- individuals. Most importantly, for individuals with hypertension, which is a major contributor to AAAD, the 4-miRNA panel also showed high accuracy in predicting those who are more likely to develop AAAD. In the blind trial set, the panel correctly classified 93.33% AAAD+ patients and 86.67% controls from the hypertension cohort. Finally, the serum miRNA-based biomarker for early AAAD detection was supported by a retrospective analysis. Taken together, we identify a distinct profile of 4-miRNA that can serve as a noninvasive biomarker for AAAD diagnosis, especially for those with hypertension.
对于急性 Stanford 型 A 型主动脉夹层 (AAAD) 患者,由于其在 48 小时内死亡率较高,因此急需早期、便捷的诊断。循环 microRNAs (miRNAs) 是心血管疾病有前途的生物标志物,然而,关于涉及 AAAD 的循环 miRNAs 知之甚少。在这里,从 104 名 AAAD+患者和 103 名年龄匹配的供体中抽取血清样本。初始筛选使用 TaqMan 低密度阵列进行,然后使用 RT-qPCR 进行确认。根据两阶段选择和验证过程,我们发现与 AAAD-个体相比,miR-25、miR-29a 和 miR-155 在 AAAD+血清样本中显着升高,而 miR-26b 则显着降低。最重要的是,对于高血压患者,这是 AAAD 的主要诱因,该 4 个 miRNA 组也显示出了较高的准确性,可以预测哪些患者更有可能发展为 AAAD。在盲法试验组中,该组正确分类了高血压组中 93.33%的 AAAD+患者和 86.67%的对照组。最后,基于血清 miRNA 的早期 AAAD 检测生物标志物得到了回顾性分析的支持。总之,我们确定了 4 个 miRNA 的独特特征,可作为 AAAD 诊断的非侵入性生物标志物,特别是对于那些患有高血压的患者。